Abstract
BackgroundHantaviruses cause acute hemorrhagic fever with renal syndrome (HFRS). Currently, several types of inactivated HFRS vaccines are widely used, however the limited ability of these immunogen to elicit neutralizing antibodies restricts vaccine efficacy. Development of an effective vaccine to overcome this weakness is must.MethodsIn the present study, a recombinant pseudotyped lentivirus bearing the hantaan virus (HTNV) envelope glycoproteins (GP), rLV-M, was constructed. C57BL/6 mice were immunized with the rLV-M and a series of immunological assays were conducted to determine the immunogenicity of the recombinant pseudotyped lentivirus. The humoral and cell-mediated immune responses induced by rLV-M were compared with those of the inactivated HFRS vaccine.ResultsIndirect immunofluorescence assay (IFA) showed the rLV-M expressed target proteins in HEK-293cells. In mice, the rLV-M efficiently induced GP-specific humoral responses and protection against HTNV infection. Furthermore, the rLV-M induced higher neutralizing antibody titers than the inactivated HFRS vaccine control.ConclusionsThe results indicated the potential of using a pseudotyped lentivirus as a delivery vector for a hantavirus vaccine immunogen.
Highlights
Hantaviruses constitute a genus of the family Bunyaviridae
Cultured cell-derived inactivated vaccines against hantaan virus (HTNV) and Seoul virus (SEOV) were developed in China, North Korea and Korea [8]
Titration of recombinant pseudotyped lentivirus containing HTNV glycoproteins HEK293 cells were infected with rLV-M, and GFPexpressing cells were detected by fluorescence microscope 48 h after infection
Summary
Hantaviruses constitute a genus of the family Bunyaviridae. Hantaviruses are spherical, enveloped viruses with a genome consisting of three segments of singlestranded, negative-sense RNA. Cultured cell-derived inactivated vaccines against HTNV and SEOV were developed in China, North Korea and Korea [8]. These vaccines induce strong humoral immune responses, but neutralizing antibodies are difficult to elicit. Researches have hypothesized that glycoproteins play an important role in eliciting neutralizing antibodies capable of protecting humans and animals from Hantavirus infection [10]. Vaccination of animals with glycoproteins of HTNV elicits neutralizing antibodies and protects rodents against infection with HTNV [13,14]. Hantavirus glycoproteins are considered protective antigens, and are the main immunogen candidates for genetically engineered vaccines targeting for hantaviruses. Development of an effective vaccine to overcome this weakness is must
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
